• 1
    Andersson K-E. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol 2004; 3: 4653
  • 2
    Cawello W, Auer S, Hammes W, Sachse R, Horstmann R. Multiple dose pharmacokinetics of fesoterodine in human subjects. Arch Pharmacol 2002; 365: R110
  • 3
    Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008; 9: 178796
  • 4
    Malhotra BK, Guan Z, Wood N, Gandelman K. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 2008; 46: 55663
  • 5
    Nilvebrant L. The mechanism of action of tolterodine. Rev Contemp Pharmacother 2000; 11: 1327
  • 6
    Pfizer Inc. Detrol LA® (Tolterodine Tartrate). Full Prescribing Information. New York: Pfizer Inc., 2008
  • 7
    Pfizer Inc. Fesoterodine fumarate (Toviaz) Smpc [Eu product label]. New York: Pfizer Inc, 2007
  • 8
    Pfizer Inc. Toviaz® (Fesoterodine fumarate). Full Prescribing Information. New York: Pfizer Inc., 2007
  • 9
    Chapple C, Van Kerrebroeck P, Tubaro A et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52: 120412
  • 10
    Nitti V, Dmochowski R, Sand P et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007; 178: 248894
  • 11
    Kelleher CJ, Tubaro A, Wang JT, Kopp Z. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int 2008; 102: 5661
  • 12
    Chapple C, Van Kerrebroeck P, Jünemann K, Wang JB. Comparison of fesoterodine and tolterodine in subjects with overactive bladder. BJU Int 2008; 102: 112832
  • 13
    Coyne KS, Tubaro A, Brubaker L, Bavendam T. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology 2006; 68: 916
  • 14
    Coyne KS, Matza L, Thompson C, Kopp Z, Jumadilova Z, Brubaker L. From an OAB patient perspective: health-related quality of life improves when frequency and urgency improve. 35th Annual Meeting of the International Continence Society; 2005 August 28-September 2; Montreal, Quebec, Canada. Available at: Accessed 18 June 2009
  • 15
    Coyne KS, Matza L, Thompson C, Bavendam T, Jumadilova Z. A comparison of three approaches to analyze urinary urgency as a treatment outcome. 35th Annual Meeting of the International Continence Society; 2005 August 28-September 2; Montreal, Quebec, Canada. Available at: https// Accessed 18 June 2009
  • 16
    Wyndaele JJ, Goldfischer ER, Morrow JD et al. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract 2009; 63: 5607
  • 17
    Herschorn S, Heesakkers J, Castro-Diaz D, Wang JT, Brodsky M, Guan Z. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms. Curr Med Res Opin 2008; 24: 351321
  • 18
    Rovner ES, Kreder K, Sussman DO et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol 2008; 180: 103441
  • 19
    Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2009; 56: 53443
  • 20
    Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006; 49: 107986
  • 21
    Cardozo L, Coyne KS, Versi E. Validation of the Urgency Perception Scale. BJU Int 2005; 95: 5916
  • 22
    Coyne K, Revicki D, Hunt T et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002; 11: 56374
  • 23
    Box GEP, Hunter WG, Hunter JS. Statistics for Experimenters. New York: Wiley, 1978
  • 24
    Van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Inst Intern Statist 1960; 37: 35161
  • 25
    Zhao YD. Sample size estimation for the van Elteren test – a stratified Wilcoxon-Mann–Whitney test. Stat Med 2006; 25: 267587
  • 26
    Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V. Determining the importance of change in the overactive bladder questionnaire. J Urol 2006; 176: 62732
  • 27
    Dmochowski RR, Peters KM, Morrow JD et al. Randomized, double-blind, placebo-controlled study of flexible-dose fesoterodine in subjects with overactive bladder. Urology 2009; Epub ahead of print. DOI: 10.1016/j.urology.2009.09.018
  • 28
    Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 54362
  • 29
    Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57: 41421
  • 30
    Kelleher CJ, Reese PR, Pleil AM, Okano GJ. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002; 8: S60815
  • 31
    Brubaker L, Chapple C, Coyne KS, Kopp Z. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 2006; 68: 38
  • 32
    Coyne KS, Elinoff V, Gordon DA et al. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. Int J Clin Pract 2008; 62: 92531
  • 33
    Pleil AM, Coyne KS, Reese PR, Jumadilova Z, Rovner ES, Kelleher CJ. The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue – the BSW. Value Health 2005; 8: S2534
  • 34
    Van Kerrebroeck PE, Kelleher CJ, Coyne KS, Kopp Z, Brodsky M, Wang JT. Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health Qual Life Outcomes 2009; 7: 13